Pharma Industry
Industry: Email Alert RSS FeedEligen With Glp-1 And Pyy3-36 Suppresses Appetite
Worldwide Biotech, July 1, 2009
Emisphere Technologies, Inc. (NASDAQ: EMIS) has announced data from a clinical study designed to assess the effect of oral administration of two peptides, GLP-1 and PYY3-36, utilizing Emisphere's Eligen Technology on appetite suppression. The study was conducted at the University Hospital in Basel, Switzerland by Professor Christoph Beglinger, of the Clinical Research Center, Department of Biomedicine Division of Gastroenterology, and Department of Clinical Pharmacology and Toxicology at the hospital.
Most RecentPharma Articles
- Allergan Sticks It to Tanning Centers: "Botax" Axed in Favor of Sun Bed Levy
- Obituaries III: La Jolla Pharmaceutical Finally Slain by the Wolf as Luck...
- The 5 Worst Drug Companies of 2009
- Ranbaxy's Christmas Turkey: FDA Again Warns Disaster-Prone Company
- Despite Guilty Plea, OxyContin CEO Claims It Was All Someone Else's Fault
- More »
The randomized, double-blind, placebo-controlled trial was conducted in 16 normal weight males between the ages of 18 and 40. The study was designed to investigate the effects of orally administered GLP-1 and PYY3-36 formulated with Emisphere's Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate carrier and their potential effect in the control of food intake and satiety. Prior studies have shown the ability of both peptides to reduce appetite and food consumption in healthy subjects and in patients with obesity.
The study concluded that these orally administered peptides, when delivered with Emisphere's SNAC carrier, were rapidly absorbed from the gastrointestinal tract, leading to concentrations several times higher than endogenous hormone levels achieved after a standard test meal. Specifically, results showed that oral GLP-1 (2 mg tablet) alone and the combination of oral GLP-1 (2 mg tablet) plus PYY3-36 (1 mg tablet) induced a significant reduction in calorie intake although there was no synergistic effect when the two peptides were used in combination. Oral PYY3-36 at a 1 mg dose by itself, did not significantly reduce calorie intake. Oral GLP-1 (2 mg tablet) and oral PYY3-36 (1 mg tablet) were both shown to induce a rapid increase in plasma GLP-1 concentrations and plasma PYY concentrations, respectively.
Professor Beglinger commented, "This latest set of data incorporating use of Emisphere's Eligen Technology in oral formulations of GLP-1 and PYY3-36 is very encouraging. Specifically, we see that oral GLP-1, as well as a combination of oral GLP-1 and PYY3-36 was sufficient to affect a meaningful reduction in calorie intake in the study subjects, indicating that further studies in appetite suppression are certainly warranted."
Michael V. Novinski, president and CEO of Emisphere, noted, "This new data represents further evidence of the ability of our Eligen Technology, and our SNAC carrier, to enhance oral absorption of peptides which normally exhibit low oral bioavailability. In this case, GLP-1 alone, and the combination of the two peptides together, were able to cross the gastrointestinal tract into the bloodstream in high enough concentrations to significantly affect appetite."
About Emisphere Technologies, Inc.
Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra- vaginal or transdermal.
For more information, visit http://www.emisphere.com or call 917/322-2563.
Brought to you by CBS MoneyWatch.com
- Best- and Worst-Paid College Degrees
- 6 Things You Should Never Do on Twitter or Facebook
- How Much Sleep Do You Really Need?
- 6 Big Myths about Gas Mileage
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Content provided in partnership with
Most Recent Technology Articles
Most Recent Technology Publications
Most Popular Technology Articles
- BizRate to monitor in-store customer satisfaction for Office Depot stores - Market Intelligence
- Speed control of separately excited DC motor
- Effects of creative, educational drama activities on developing oral skills in primary school children
- Political stability and economic growth in Asia
- Failed businesses in Japan: a study of how different companies have failed, and tips on how to succeed, in the Japanese market



